Tag Archives: kidney

‘Silent disease’: Many have kidney disease, but don’t know till it’s too late | HeraldNet.com – The Daily Herald

  1. ‘Silent disease’: Many have kidney disease, but don’t know till it’s too late | HeraldNet.com The Daily Herald
  2. Silent Pandemic Surges To Third-Fastest Growing Cause Of Death Globally Daily Caller
  3. International Consensus Statement Published in Nature Reviews Nephrology Calls for Urgent Action to Address Chronic Kidney Disease on the Global Public Health Agenda Newswise
  4. International consensus statement calls for urgent action to address CKD Healio
  5. World Kidney Day Theme “Kidney Health For All: Advancing Equitable Access To Care And Optimal Medication Practice” Magnetic Media

Read original article here

Spokane doctor’s kidney treatment will be tested in 11000-person study – The Seattle Times

  1. Spokane doctor’s kidney treatment will be tested in 11000-person study The Seattle Times
  2. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial The Lancet
  3. ‘On par with the biggest breakthroughs in medicine’: Spokane doctor discovers new kidney disease treatment. An 11000-person study will start in 2024 The Spokesman Review
  4. Significant benefit seen in Phase III trial of experimental drug for kidney disease Medical Xpress
  5. Kidney Disease Drug Candidate Shows Broad Inhibition of Damaging Hormone Inside Precision Medicine

Read original article here

Ozempic’s early success in kidney disease trial hits dialysis stocks – Yahoo Finance

  1. Ozempic’s early success in kidney disease trial hits dialysis stocks Yahoo Finance
  2. Novo Nordisk stops Ozempic kidney trial after early signs of success Reuters
  3. Pharmalittle: Novo halts Ozempic kidney failure trial after early signs of success; GSK settles California Zantac lawsuit STAT
  4. Dialysis Providers’ Stocks Drop as Novo Nordisk (NYSE:NVO) Halts Ozempic Study – TipRanks.com TipRanks
  5. Novo Nordisk will stop the once-weekly injectable semaglutide kidney outcomes trial, FLOW, based on interim analysis GlobeNewswire
  6. View Full Coverage on Google News

Read original article here

Francia Raisa says Selena Gomez fallout had nothing to do with kidney – Entertainment Weekly News

  1. Francia Raisa says Selena Gomez fallout had nothing to do with kidney Entertainment Weekly News
  2. Francia Raisa says falling out with Selena Gomez ‘had nothing to do with the kidney’: A look at their ups and downs Yahoo Entertainment
  3. Francia Raisa Clears the Air About Selena Gomez, Shakira At Latin Music Week & More | Billboard News Billboard
  4. Francia Raisa and Selena Gomez Had ‘Zigzags in Life’ but Remain Friends Like ‘Old Times’ (Exclusive) PEOPLE
  5. Francia Raisa Says ROCKY Times with Selena Gomez NOT About Kidney (Exclusive) extratv
  6. View Full Coverage on Google News

Read original article here

Pig kidney still functioning in brain-dead man 6 weeks after transplant surgery: ‘Extremely encouraging’ – Fox News

  1. Pig kidney still functioning in brain-dead man 6 weeks after transplant surgery: ‘Extremely encouraging’ Fox News
  2. Revolutionizing Renal Care: Can an Artificial Kidney Finally Free Patients From Dialysis? SciTechDaily
  3. A Pig Kidney Was Just Transplanted Into a Human Body, And It Is Still Working Scientific American
  4. Artificial kidney is a success in pigs, what about humans? Interesting Engineering
  5. Implantable bioreactor study works toward a bioartificial kidney to free patients from dialysis Medical Xpress
  6. View Full Coverage on Google News

Read original article here

‘Aquaman’ Actor Dolph Lundgren Reveals Kidney Cancer Diagnosis, Hopes Going Public Can “Save One Person’s Life” – Hollywood Reporter

  1. ‘Aquaman’ Actor Dolph Lundgren Reveals Kidney Cancer Diagnosis, Hopes Going Public Can “Save One Person’s Life” Hollywood Reporter
  2. Dolph Lundgren says he wanted to ‘knock out’ Sylvester Stallone while filming ‘The Expendables’: ‘I’m just gonna punch him out and leave’ Yahoo! Voices
  3. Dolph Lundgren reveals cancer battle CNN
  4. Dolph Lundgren reveals secret 8 year cancer battle, how a second opinion saved his life Fox News
  5. Dolph Lundgren, ‘Rocky IV’ actor who played Ivan Drago, reveals secret 8-year cancer battle Yahoo Entertainment
  6. View Full Coverage on Google News

Read original article here

Travere Therapeutics drug approved for rare kidney disease – STAT – STAT

  1. Travere Therapeutics drug approved for rare kidney disease – STAT STAT
  2. Travere Therapeutics Announces FDA Accelerated Approval of FILSPARITM (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy Yahoo Finance
  3. With FDA approval for Filspari, Travere turns Bristol Myers castoff into unique drug for rare kidney disease FiercePharma
  4. US FDA approves Travere Therapeutics kidney disorder drug TODAY
  5. Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy Yahoo Finance
  6. View Full Coverage on Google News

Read original article here

With FDA approval for Filspari, Travere turns Bristol Myers castoff into unique drug for rare kidney disease – FiercePharma

  1. With FDA approval for Filspari, Travere turns Bristol Myers castoff into unique drug for rare kidney disease FiercePharma
  2. Travere Therapeutics drug approved for rare kidney disease – STAT STAT
  3. Travere Therapeutics Announces FDA Accelerated Approval of FILSPARITM (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy Yahoo Finance
  4. US FDA approves Travere Therapeutics kidney disorder drug TODAY
  5. Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy Yahoo Finance
  6. View Full Coverage on Google News

Read original article here

Scientists suggest eating oily fish linked to lower risk of kidney disease | Medical research

Eating at least two portions of oily fish such as mackerel, sardines or herrings a week is linked to a lower risk of chronic kidney disease and a slower decline in the organ’s function, research suggests.

Chronic kidney disease (CKD) affects about 700 million people worldwide. It can lead to kidney failure and death, so there is an urgent need to identify factors that could prevent its onset and progression.

Now a study has found an association between higher levels of omega 3 fatty acids found in oily fish and other seafood, and a reduced risk of kidney problems. The link was not found with higher levels of plant-derived omega 3 fatty acids.

The findings of the international team of researchers, which was led by the George Institute for Global Health and the University of New South Wales, were published in the medical journal the BMJ.

“While we cannot for certain say what specific fishes had the greatest effect on CKD risk, we know that the blood levels of the fatty acids reflect their intake well,” Dr Matti Marklund, a senior research fellow at the George Institute, told the Guardian in an email.

“Among the richest dietary sources of these fatty acids are fatty cold-water fish – for example, salmon, sardines, mackerel, and herrings – and to a less extent shellfish, like oysters, mussels, and crab.”

The findings support guidelines recommending consumption of oily fish and other seafood as part of a healthy diet.

“Current dietary recommendations in most countries suggest at least two servings of fish per week, preferably oily fish, which will provide about 250mg/day of long-chain omega 3s,” said Marklund.

Studies in animals have previously suggested omega 3 fatty acids may help with kidney function, but until now evidence from human research was limited – and relied mostly on dietary questionnaires.

The researchers pooled the results of 19 studies from 12 countries examining links between levels of omega 3 fatty acids and the development of CKD in adults.

About 25,000 people were included in the main analysis, aged between 49 and 77.

After accounting for a range of factors including age, sex, race, body mass index, smoking, alcohol intake, physical activity, heart disease and diabetes, higher levels of seafood omega 3 fatty acids were associated with an 8% lower risk of developing CKD.

When participants were split by levels of seafood omega 3 fatty acids consumed, those in the highest fifth had a 13% lower risk of CKD compared with those in the lowest fifth. Higher levels were also associated with a slower annual decline in kidney function.

The researchers pointed out that their findings were observational and therefore did not prove that including more seafood in your diet definitely lowers the risk of CKD. “We need randomised controlled trials to determine that type of causality,” Marklund said.

Nevertheless, results were similar after further analysis, and appeared consistent across age groups. “Higher levels were consistently associated with lower CKD risk,” he added.

Read original article here

Would You Sell Your Extra Kidney?

When we were teenagers, my brother and I received kidney transplants six days apart. It wasn’t supposed to be that way. He, two years older, was scheduled to receive my dad’s kidney in April of 1998. Twenty-four hours before the surgery, the transplant team performed its final blood panel and discovered a tissue incompatibility that all the previous testing had somehow missed. My brother was pushed onto “the list,” where he’d wait, who knows how long, for the kidney of somebody who had died and possessed the generous foresight to be a donor after death. I was next in line for my dad’s kidney. We matched, and the date was set for August 28. Then my parents got a call early in the morning on August 22. There had been a car crash. A kidney was available. As with many things in life, my brother went first and I followed.

His operation went smoothly. Six days later, it was my turn. I remember visiting the doctor shortly before the transplant, feeling the pinprick and stinging flush of local anesthetic, then a blunted tugging, the nauseating and strange sensation of a dialysis catheter withdrawn from below my collarbone. I remember, later, the tranquil fog of midazolam as I was rolled to the OR. 

I remember waking from great depths after surgery under bright lights and shivering violently, then falling back asleep. I remember lying naked under blankets in the ICU, mildly delirious from morphine while watching a movie about a plane crash in the Alaskan wilderness, with Anthony Hopkins and Alec Baldwin fleeing a giant grizzly bear. I remember friends visiting me on the recovery floor, and how it hurt to laugh.

But now that 24 years have passed, all in relatively good health, I can recognize how much I’ve forgotten. I forget the short leash of dialysis from the months before my transplant: those oversize recliners deep inside the taupe core of a hospital building where, three times a week, machines drained and recycled my blood. I forget the plainness of a low-potassium, low-phosphorus, low-salt diet. I forget how bizarre it is that a few pills in the morning and a few at night keep the foreign organ in my lower abdomen alive—keep me alive. I, regrettably, lose sight of the supreme gift I’ve been given, this indefinite allowance of extra time, while 90,000 other Americans wait for this same gift, often on dialysis for years. Roughly 4 percent will die every year still waiting, and another 4 percent will become too sick to undergo major surgery. But here I am, forgetting this grace.

Five years ago, my brother’s kidney began to fail, and all of these buried memories resurfaced. His blood tests returned erratic levels, and nephrologists fretted. He was in and out of the hospital with recurring viral infections. A biopsy revealed necrotic tissue perforating half his kidney, webbed throughout like the tunnels of an ant colony. Finally, in May of 2018, he sent an email to family and friends, distilling the two borrowed decades during which he had attended concerts, hiked the Pacific Northwest, fallen in love, gotten married, started a family. All of these details were offered with a kind of chummy lightheartedness, but, as every reader knew, they barreled toward the inevitable and awkward conclusion. He was 37 years old and back in the hunt for a kidney. Would you be so kind as to consider … ?

The first successful kidney transplant took place in Boston in 1954 between a deliriously ill Richard Herrick and his identical twin brother, Ronald. Eight years later, his new kidney still doing its job, Richard died of a heart attack. Scattered attempts had come before then. In Ukraine, in 1933, the kidney of a 60-year-old man with type B blood who’d been dead for six hours was transplanted into a 26-year-old woman with type O blood who’d lost kidney function after poisoning herself. The recipient survived for two more days, which is miraculous considering the technology, circumstances, and general knowledge at the time. A transplant recipient in Chicago, in 1950, had some additional kidney function for a few months. Paris became a hotbed of experimentation in the early ’50s. Then came the Herricks.

Their story was technically dazzling but left unsolved the central biological puzzle of transplantation: how to tame the immune system. In most cases, our bodies recognize foreign tissue and send a battery of B and T cells to kill it. As identical twins with identical-enough tissue types, the Herricks sidestepped this problem. But doctors would need a solution to our innate immune response if kidney transplants were ever to become a mainstream procedure. Early efforts subjected patients to full-body preoperative blasts of X-ray radiation at borderline-lethal doses. The intent was to crush the immune system, then let it rebuild with the new kidney in place. This was sometimes accompanied by an injection of bone marrow. Most patients died from organ rejection, graft-versus-host disease, or both. The field of transplant surgery grew insular and desperate. Citing the fundamental precept of avoiding unnecessary harm, the more conservative medical practitioners of the day vilified the practice. Around this time, one detractor wondered, “When will our colleagues give up this game of experimenting on human beings? And when will they realize that dying, too, can be a mercy?”

Read original article here